BridgeBio Pharma Raises $299.2 Million to Support Its Genetic Disease Development Programs

BridgeBio Pharma Raises $299.2 Million to Support Its Genetic Disease Development Programs

Source: 
CP Wire
snippet: 


BridgeBio Pharma, a clinical-stage biopharmaceutical company focused on genetic diseases, today announced a new financing round of $299.2 million. The round was co-led by existing investors KKR and Viking Global Investors. Other existing investors participating included Perceptive Advisors, AIG, Aisling Capital, Cormorant Capital, and Hercules Capital; and they were joined by new investors Sequoia Capital, and a blue-chip long-term investor.